Detalhe da pesquisa
1.
Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Endocr Pract
; 27(9): 886-893, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581327
2.
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Adv Ther
; 38(7): 3900-3910, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34061324
3.
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Expert Rev Gastroenterol Hepatol
; 15(6): 589-598, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33666530
4.
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
J Immunother Cancer
; 9(2)2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563773
5.
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.
Cancers (Basel)
; 13(9)2021 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33919277